The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets

开始日期2025-01-15

申办/合作机构

Centre Hospitalier de Pau

NCT06459609 / Not yet recruitingN/AIIT

Effect of Protein Supplementation on Craving in Subjects Hospitalised for Addiction Treatment. Monocentric Pilot Study.

Moncentric pilot study conducted in the addictology department of the Pau Hospital, designed to demonstrate the benefit of protein supplementation on craving in patients with a substance use disorder at the start of their treatment for addiction.
This study will be conducted according a crossover design with a one-week phase with protein supplementation (P) and a one-week phase without protein supplementation (SP).

开始日期2024-09-01

申办/合作机构

Centre Hospitalier de Pau

NCT06193785 / RecruitingN/AIIT

Evaluation of Hypnosis Practice During a Semi-invasive and Painful Medical Examination in Neurology: the Electromyogram

Electromyogram is a current exam usually in neurological practices use for study peripheral nervous system. This is a semi-invasive examination causing pain. The aim of the study is to evaluate hypnosis practice in patients during an electromyogram. The investigator will evaluate pain with quantitative and qualitative evaluation in two groups with and without hypnosis in an open, quasi-randomised prospective therapeutic study in Pau hospital centre

开始日期2024-03-25

申办/合作机构

Centre Hospitalier de Pau

100 项与 Centre Hospitalier de Pau 相关的临床结果

登录后查看更多信息

0 项与 Centre Hospitalier de Pau 相关的专利（医药）

登录后查看更多信息

142

项与 Centre Hospitalier de Pau 相关的文献（医药）

2024-09-06·The Oncologist

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer

Article

作者: Baba-Hamed, Nabil ; Desauw ; Legoux, Jean-Louis ; Michel, Pierre ; Mary, Florence ; Bernard, Philippe ; Corbinais, Stéphane ; Turpin, Anthony ; Williet, Nicolas ; Lagasse, Jean-Paul ; Moullet, Isabelle ; Baize, Nathalie ; Seitz, Jean-François ; Arsenii, Nicolae ; Baconnier, Mathieu ; Pezet, Denis ; Romano, Olivier ; Vimal-Baguet, Agnès ; Dahan, Laetitia ; Simon, Mireille ; Lièvre, Astrid ; Ceban, Tatiana ; Bourgeois, Vincent ; Berdah, Stéphane ; Rinaldi, Yves ; Bedenne, Laurent ; Thomas Marques, Laurence ; Bignon, Anne-Laure ; Desgrippes, Romain ; Bouché, Olivier ; Hollebecque, Antoine ; Bouhier-Leporrier, Karine ; Cattan, Stéphane ; Dupont Kazma, Laure ; Boisteau, Emeric ; Talarmin, Marie ; Lecomte, Thierry ; Devaure, Iris ; Charlois, Thierry ; Artru, Pascal ; Sefrioui, David ; Le Sourd, Samuel ; Villing, Anne-Laure ; Walter, Thomas ; Audemar, Franck ; Zaanan, Aziz ; Guillet, Marielle ; Breysacher, Gilles ; Meunier, Jérôme ; Lombard-Bohas, Catherine ; Durand, Aurelie ; Lledo, Gérard ; Hocine, Fayçal ; Le Roy, Florence ; Pigui, Anna ; Ferte, Charles ; Burtin, Pascal ; Bachet, Jean-Baptiste ; Remy, Stéphane ; Guilngar, Anne ; Sverdlin, Robert ; Ducreux, Michel ; Boige, Valérie ; Desramé, Jérôme ; Molin, Yann ; Petorin, Caroline ; Plastaras, Laurianne ; Barriere, Nicolas ; Malka, David ; Cavaglione, Gérard ; Le Malicot, Karine ; Coufon, Caroline ; Dupont Gossart, Anne-Claire ; Gigout, Julie ; Pracht, Marc ; Andrau, Pierre ; Taieb, Julien ; Boulat ; Aparicio, Thomas ; Follana, Philippe ; Duluc, Muriel ; Jouve, Jean-Louis ; Cornila, Corina ; Lepage, Côme ; Topolski, Amalia ; Norguet, Emmanuelle ; Staudacher, Lionel ; Cumin, Isabelle ; Lecaille, Cédric ; Hebbar, Mohamed ; Locher, Christophe ; Rebischung, Christine ; François, Eric ; Escande, Anne ; Evesque, Ludovic ; Sibertin-Blanc, Camille ; Foll, Le ; Farneti, Delphine ; Deplanque, Gaël ; Duchmann, Jean-Christophe ; Belletier ; Ezenfis, Joël ; Granger, Victoire ; Bonnet, Isabelle

AbstractIntroductionPredictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy.Patients and MethodsWe focused on patients who received 12 cycles of FOLFIRINOX (arm A, N = 88) or 8 cycles of FOLFIRINOX followed by LV5FU2 maintenance in controlled patients (arm B, N = 91) from the PRODIGE-35 trial. Prognostic factors and predictors of efficiency were identified by using Cox regression. Median progression-free survival (PFS), overall survival (OS), and time to deterioration of quality of life (TTD-QoL) were evaluated.ResultsPoor independent prognostic factors were primary tumor in place, age <65 years and the presence of liver metastases for PFS, a baseline neutrophil/lymphocyte ratio (NLR) ≥5 and CA19.9 ≥500 UI/L for OS, independent of the treatment arm. Patients with one metastatic site had a longer PFS in arm A, whereas patients with ≥2 metastatic sites had a longer PFS in arm B. We also identified predictors of OS and TTD-QoL in arm B but these differences were not statistically significant.ConclusionExcept for patients with one metastatic site who benefited more from 12 cycles of FOLFIRINOX, a maintenance strategy with LV5FU2 should be widely offered to mPC patients whose survival and QoL are preserved after 4 months of FOLFIRINOX. (ClinicalTrials.gov: NCT02352337).

2024-06-01·Breast Cancer Research and Treatment

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

Article

作者: Pistilli, Barbara ; Arsene, Olivier ; Nguyen, Suzanne ; Durando, Xavier ; Ginzac, Angeline ; Levy, Christelle ; Tixier, Lucie ; Penault-Llorca, Frédérique ; Campone, Mario ; Jouannaud, Christelle ; Petit, Thierry ; Motte Rouge, Thibault De La ; Mahier Ait Oukhatar, Céline ; Venat Bouvet, Laurence ; Nabholtz, Jean-Marc ; Cayre, Anne ; Bonichon-Lamichhane, Nathalie ; Augereau, Paule ; Mouret-Reynier, Marie-Ange ; D'hondt, Véronique ; Molnar, Ioana

AbstractPurposePrevious studies have reported the benefit of dual HER2-targeting combined to neoadjuvant chemotherapy in HER2-amplified breast cancer (HER2 + BC). Moreover, besides the cardiac toxicity following their association to Trastuzumab, anthracyclines chemotherapy may not profit all patients. The NeoTOP study was designed to evaluate the complementary action of Trastuzumab and Pertuzumab, and the relevance of an anthracycline-based regimen according to TOP2A amplification status.MethodsOpen-label, multicentre, phase II study. Eligible patients were aged ≥ 18 with untreated, operable, histologically confirmed HER2 + BC. After centralized review of TOP2A status, TOP2A-amplified (TOP2A+) patients received FEC100 for 3 cycles then 3 cycles of Trastuzumab (8 mg/kg then 6 mg/kg), Pertuzumab (840 mg/kg then 420 mg/kg), and Docetaxel (75mg/m2 then 100mg/m2). TOP2A-not amplified (TOP2A-) patients received 6 cycles of Docetaxel (75mg/m2) and Carboplatin (target AUC 6 mg/ml/min) plus Trastuzumab and Pertuzumab. Primary endpoint was pathological Complete Response (pCR) using Chevallier’s classification. Secondary endpoints included pCR (Sataloff), Progression-Free Survival (PFS), Overall Survival (OS), and toxicity.ResultsOut of 74 patients, 41 and 33 were allocated to the TOP2A + and TOP2A- groups respectively. pCR rates (Chevallier) were 74.4% (95%CI: 58.9–85.4) vs. 71.9% (95%CI: 54.6–84.4) in the TOP2A + vs. TOP2A- groups. pCR rates (Sataloff), 5-year PFS and OS were 70.6% (95%CI: 53.8–83.2) vs. 61.5% (95%CI: 42.5–77.6), 82.4% (95%CI: 62.2–93.6) vs. 100% (95%CI: 74.1–100), and 90% (95%CI: 69.8–98.3) vs. 100% (95%CI: 74.1–100). Toxicity profile was consistent with previous reports.ConclusionOur results showed high pCR rates with Trastuzumab and Pertuzumab associated to chemotherapy. They were similar in TOP2A + and TOP2A- groups and the current role of neoadjuvant anthracycline-based chemotherapy remains questioned.Trial registration numberNCT02339532 (registered on 14/12/14).

2024-01-01·Journal Français d'Ophtalmologie

Artérite gigantocellulaire compliquée d’ischémie du segment antérieur : à propos d’un cas

Letter

作者: Simon, A F ; Williamson, W ; Chan, G

100 项与 Centre Hospitalier de Pau 相关的药物交易

登录后查看更多信息

100 项与 Centre Hospitalier de Pau 相关的转化医学

登录后查看更多信息